Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks.com  from a “buy” ranking to a “hold” ranking in a research note provided to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on uncovering and also creating tiny particle drug candidates to treat cancer. The Firm‘s items under different stages of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research experts additionally lately discussed the company. Noble Financial editioned a “buy” ranking and issued a $11.00 cost purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “purchase” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day moving typical rate of $2.90 and also a two-hundred day relocating average rate of $4.16. The business has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, covering analysts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and a negative net margin of 8,294.27%. The company had profits of $0.06 million during the quarter, compared to the agreement quote of $0.06 million. Throughout the exact same quarter in the previous year, the firm published ($ 0.45) EPS. En masse, research experts anticipate that Onconova Therapeutics will post -1.18 EPS for the existing year.

A number of hedge funds have actually lately dealt shares of ONTX. GSA Capital Allies LLP got a brand-new position in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Monitoring LP got a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a brand-new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and other institutional investors possess 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which takes part in the recognition as well as development of oncology therapeutics. It concentrates on finding as well as developing small particle drug prospects to deal with cancer cells. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more about research offerings from Zacks Investment Research, go to Zacks.com.

This instant information alert was created by narrative science technology and also economic information from Market in order to offer visitors with the fastest and most precise reporting. This tale was reviewed by Market’s editorial team prior to publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS NOW?

Before you think about Onconova Therapeutics, you’ll want to hear this.

Market tracks Wall Street’s premier as well as ideal performing research analysts and also the stocks they advise to their clients daily. Market has actually determined the 5 stocks that cover experts are silently whispering to their clients to acquire currently before the broader market catches on … and also Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics presently has a “Buy” score among analysts, top-rated experts think these five stocks are better buys.